Thyrotoxicosis.

Thyrotoxicosis is any state of excess circulating thyroid hormone, regardless of source. Hyperthyroidism is the subset caused by overproduction of hormone by the thyroid gland itself, such as Graves disease or toxic nodular disease. Thyroiditis and exogenous hormone overdose produce thyrotoxicosis without hyperthyroidism, because the gland is not overproducing.

Early signs include unexplained weight loss, a fast resting heart rate, heat intolerance, fine hand tremor, anxiety, irritability, and difficulty sleeping. Older adults often present only with new-onset atrial fibrillation or apathy. A suppressed TSH on routine blood work confirms the suspicion and prompts further testing for cause.

Diagnosis follows two steps. First, blood tests showing a suppressed TSH below 0.1 mIU/L with elevated free T4 or free T3 confirm thyrotoxicosis. Second, the cause is identified using TSH-receptor antibody testing, radioiodine uptake scanning, or thyroid ultrasound with Doppler. Most patients have a clear diagnosis within 1-2 weeks of presentation.

There is no single best treatment. The three options — antithyroid drugs, radioactive iodine, and total thyroidectomy — all have cure rates above 90%. Choice depends on age, pregnancy plans, severity, presence of orbitopathy, and patient preference. Most patients begin with methimazole; about half of Graves patients remit after 12-18 months of treatment.

Radioactive iodine (I-131) has been used since 1941 and is one of the most studied treatments in medicine. It does not increase the long-term risk of cancer or infertility at standard treatment doses. It is contraindicated in pregnancy and breastfeeding, and may worsen active Graves orbitopathy unless steroid cover is given. Most patients become hypothyroid within a year and take daily levothyroxine.

Yes. Radioiodine cures over 90% of Graves and toxic nodular thyrotoxicosis with a single dose, and total thyroidectomy cures over 95%. Both leave patients hypothyroid, requiring daily levothyroxine. Antithyroid drugs induce sustained remission in 40-50% of Graves patients after 12-18 months of treatment.

Thyroid storm is a life-threatening decompensation of thyrotoxicosis with fever above 38.5°C, heart rate over 130, agitation or altered mental status, vomiting, and multiorgan dysfunction. It is usually precipitated by infection, surgery, or radioiodine in untreated patients. Mortality is 10-30%. Treatment is intensive-care with propylthiouracil, beta-blockers, iodine, and glucocorticoids.

TSH-receptor antibodies cross-react with fibroblasts behind the eye, causing inflammation and accumulation of glycosaminoglycans and fat in the orbital tissues. The expanded tissue pushes the eye forward (proptosis), retracts the eyelids, and can compress the optic nerve. Smoking triples the risk of severe orbitopathy, and quitting is the single most effective intervention.

Yes. Human chorionic gonadotropin (hCG) weakly stimulates the thyroid, and high hCG levels in the first trimester can transiently suppress TSH (gestational transient thyrotoxicosis). Hyperemesis gravidarum and trophoblastic disease produce the highest hCG levels. Persistent thyrotoxicosis through pregnancy is most often Graves disease, which requires careful management with propylthiouracil in the first trimester.

Symptoms such as palpitations and tremor improve within days when a beta-blocker is added. Biochemical markers (free T4 and free T3) begin to fall after 2-4 weeks of methimazole. Full euthyroidism is reached in 6-12 weeks, after which the dose is tapered to a maintenance level of 5-10 mg daily.

Yes, although women are diagnosed 5-10 times more often. Men with thyrotoxicosis are more likely to develop severe complications including atrial fibrillation, congestive heart failure, and moderate-to-severe Graves orbitopathy. Diagnosis is sometimes delayed in men because the syndrome is less expected. Treatment options and outcomes are the same.

Limit high-iodine foods including kelp, seaweed, dulse, and supplements containing iodine or so-called thyroid support formulas. Excess caffeine worsens palpitations and insomnia. Once on antithyroid drugs and approaching euthyroidism, no specific foods are forbidden, although ongoing moderation with alcohol is sensible due to bone effects.

If treated with radioiodine or thyroidectomy, you will take daily levothyroxine for life because the thyroid no longer produces enough hormone. If treated with antithyroid drugs and you achieve sustained remission, you may need no ongoing medication, although TSH should be monitored annually because relapse is common.

Major life stress has been linked to onset of Graves disease in case-control studies, likely by disturbing immune regulation. Stress alone does not cause thyrotoxicosis but may help trigger it in genetically predisposed people. Stress management remains useful for symptom control and quality of life but is not a substitute for medical treatment.

Graves disease has a clear genetic component, with heritability estimated at 60-80% from twin studies. First-degree relatives of Graves patients have a 5-10 fold increased risk. Variants in HLA-DR3, CTLA4, PTPN22, and TSH-receptor genes are the main susceptibility loci. Toxic nodular disease has a weaker hereditary signal.

Untreated thyrotoxicosis leads to progressive weight loss, muscle wasting, osteoporosis, atrial fibrillation, heart failure, and a 20% mortality at 10 years from cardiovascular causes. Risk of thyroid storm rises with infections, surgery, or trauma. Early diagnosis and treatment prevent virtually all of these outcomes.

Yes. Pediatric Graves disease affects approximately 1 in 10,000 children, peaking in adolescence and predominating in girls. Presentation includes weight loss, poor concentration, declining school performance, and behavioral change. Methimazole is first-line; radioiodine and surgery are reserved for treatment failure or relapse.

Yes. Diffuse non-scarring hair thinning over the scalp affects up to 50% of patients with significant thyrotoxicosis. Hair becomes fine and breaks easily. Loss is reversible: hair density recovers within 6-12 months of restoring euthyroid status. Persistent hair loss after treatment should prompt evaluation for other causes.

Avoid vigorous exercise while resting heart rate is above 100 bpm. Once heart rate is controlled with beta-blockers or definitive treatment, moderate aerobic and resistance exercise is encouraged for bone and muscle preservation. Patients with cardiac complications should clear with their clinician before resuming exercise.

During antithyroid drug titration, TSH and free T4 are checked every 4-6 weeks. Once stable on a maintenance dose, testing every 3 months is sufficient. After radioiodine, monitor every 4-6 weeks until euthyroid or until levothyroxine replacement begins. Liver function and complete blood count are checked at baseline and if symptoms suggest adverse effects.